Richard A. Larson

机构：University of Chicago · ORCID：0000-0001-9168-3203

发表论文 1472 篇 · 总被引 116316 次 · h-index 145

代表论文

• Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations (2024 · Blood · 被引 242)
• Asciminib in Newly Diagnosed Chronic Myeloid Leukemia (2024 · New England Journal of Medicine · 被引 164)
• 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia (2025 · Leukemia · 被引 133)
• Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study (2025 · Blood · 被引 65)
• Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults (2025 · Blood Cancer Journal · 被引 15)
• Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial (2025 · Blood · 被引 14)